Evidence map›Paper›PMID 34998485›Full record

ArticleThe Lancet. Public health2022

Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019.

GBD 2019 Dementia Forecasting Collaborators

4 registry-linked trialsOpen access · goldAbstract read
In one paragraph

Article in The Lancet. Public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 3,123 papers, 12 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3,123citing papers in PubMed, 12 pooled it
654.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06379100 nacompletednot on this mapstarted 2024, after this paper: background citation

A Randomized, Controlled Clinical Study on Cerebellar ITBS Mode Transcranial Magnetic Stimulation for the Treatment of Alzheimer's Disease

TypeinterventionalSponsorXijing HospitalRan2024 to 2024Enrolled20ConditionsTranscranial Magnetic Stimulation, Alzheimer Disease, Magnetic Resonance Imaging, ElectroencephalogramArmstranscranial magnetic stimulation
NCT06588946 phase2not yet recruitingnot on this mapstarted 2025, after this paper: background citation

The Effect of Exogenous Β-OHB Supplementation on Cerebral Blood Flow and Functional Brain Characteristics in Adults with Subjective Cognitive Decline

TypeinterventionalSponsorMcMaster UniversityRan2025 to 2027Enrolled48ConditionsSubjective Cognitive DeclineArmsKetone monoester (KME) supplement, Placebo supplement
NCT06669182 narecruitingnot on this mapstarted 2025, after this paper: background citation

Effects of Cerebellar Transcranial Magnetic Stimulation on Patients With Alzheimer's Disease:A Multicenter Randomized Controlled Trial

TypeinterventionalSponsorXijing HospitalRan2025 to 2026Enrolled100ConditionsAlzheimer Disease, Transcranial Magnetic Stimulation, CerebellumArmsIntermittent Theta-Burst Transcranial Magnetic Stimulation
NCT07612800 nanot yet recruitingnot on this mapstarted 2026, after this paper: background citation

Tailored Brain Health Insights Through Nurturing Knowledge-based Change - Stakeholder-driven, Human-centered, AI-powered Refinement for Prevention (THINK-SHARP)

TypeinterventionalSponsorAlexandra HospitalRan2026 to 2029Enrolled350ConditionsMCI, DementiaArmsBLAZE (Brain health Lifestyle Action with personaliZed Engagement)
3 · Its place in the literature

Who cites it

3,123 citing papers in PubMed, 12 syntheses or guidelines pooled it, 4,766 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Trial
  14. Trial
  15. Article
  16. Exploring the experiences and needs in everyday life of spouse carers of persons with dementia.International journal of qualitative studies on health and well-being · 2026
    Article
  17. Article
  18. Article
  19. Article
  20. FermentedPharmaceutical biology · 2026
    Article

3,063 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

GBD 2019 Dementia Forecasting Collaborators
University of Washington · US

Funding

EPIDEMIOLOGY AND BIOSTATISTICS OF AGINGT32AG000247 · NIA · JOHNS HOPKINS UNIVERSITY · PI Karen J. Bandeen-Roche · 1996 to 2026
$13.2M
Mapping impact and developing mitigation strategies for climate change-mental health nexus in the context of vulnerable adolescent populations in KenyaK43TW010716 · FIC · UNIVERSITY OF NAIROBI · PI KUMAR, MANASI · 2018 to 2022
$648k
Department of HealthFIC NIH HHS K43 TW010716Medical Research Council MC_PC_MR/T03355X/1Medical Research Council MR/S011676/1NIA NIH HHS T32 AG000247Wellcome Trust
6 · The paper itself

Abstract

backgroundGiven the projected trends in population ageing and population growth, the number of people with dementia is expected to increase. In addition, strong evidence has emerged supporting the importance of potentially modifiable risk factors for dementia. Characterising the distribution and magnitude of anticipated growth is crucial for public health planning and resource prioritisation. This study aimed to improve on previous forecasts of dementia prevalence by producing country-level estimates and incorporating information on selected risk factors.

methodsWe forecasted the prevalence of dementia attributable to the three dementia risk factors included in the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019 (high body-mass index, high fasting plasma glucose, and smoking) from 2019 to 2050, using relative risks and forecasted risk factor prevalence to predict GBD risk-attributable prevalence in 2050 globally and by world region and country. Using linear regression models with education included as an additional predictor, we then forecasted the prevalence of dementia not attributable to GBD risks. To assess the relative contribution of future trends in GBD risk factors, education, population growth, and population ageing, we did a decomposition analysis.

findingsWe estimated that the number of people with dementia would increase from 57·4 (95% uncertainty interval 50·4-65·1) million cases globally in 2019 to 152·8 (130·8-175·9) million cases in 2050. Despite large increases in the projected number of people living with dementia, age-standardised both-sex prevalence remained stable between 2019 and 2050 (global percentage change of 0·1% [-7·5 to 10·8]). We estimated that there were more women with dementia than men with dementia globally in 2019 (female-to-male ratio of 1·69 [1·64-1·73]), and we expect this pattern to continue to 2050 (female-to-male ratio of 1·67 [1·52-1·85]). There was geographical heterogeneity in the projected increases across countries and regions, with the smallest percentage changes in the number of projected dementia cases in high-income Asia Pacific (53% [41-67]) and western Europe (74% [58-90]), and the largest in north Africa and the Middle East (367% [329-403]) and eastern sub-Saharan Africa (357% [323-395]). Projected increases in cases could largely be attributed to population growth and population ageing, although their relative importance varied by world region, with population growth contributing most to the increases in sub-Saharan Africa and population ageing contributing most to the increases in east Asia.

interpretationGrowth in the number of individuals living with dementia underscores the need for public health planning efforts and policy to address the needs of this group. Country-level estimates can be used to inform national planning efforts and decisions. Multifaceted approaches, including scaling up interventions to address modifiable risk factors and investing in research on biological mechanisms, will be key in addressing the expected increases in the number of individuals affected by dementia.

fundingBill & Melinda Gates Foundation and Gates Ventures.

Indexed as

Global HealthSmokingBlood GlucoseBody Mass IndexDementiaEducational StatusGlobal Burden of DiseaseHumansPopulation DynamicsRisk FactorsSociodemographic FactorsBlood Glucose

Identifiers

PMID34998485
PMCPMC8810394
OpenAlexW4206055706

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.